Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Time to 'get real': preliminary insights into the long-term management of schizophrenia.

Malhi G, Adams D, Bernardi E, Miller M, Mulder R, Walter G, Smith B.

Australas Psychiatry. 2010 Apr;18(2):115-9. doi: 10.3109/10398560903450866.

PMID:
20158434
2.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients..

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

3.

Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.

Wheeler AJ.

Ann Pharmacother. 2008 Jun;42(6):852-60. doi: 10.1345/aph.1K662. Epub 2008 May 13.

PMID:
18477732
4.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
5.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
6.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders..

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

7.

[Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].

Mercier C, Bret P, Bret MC, Queuille E.

Encephale. 2009 Sep;35(4):321-9. doi: 10.1016/j.encep.2008.10.007. Epub 2009 Feb 7. French.

PMID:
19748368
8.

Clinical profiles, scope and general findings of the Western Sydney First Episode Psychosis Project.

Harris A, Brennan J, Anderson J, Taylor A, Sanbrook M, Fitzgerald D, Lucas S, Redoblado-Hodge A, Gomes L, Gordon E.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):36-43.

PMID:
15660704
9.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
10.

Long-term treatment of mood disorders in schizophrenia.

Azorin JM.

Acta Psychiatr Scand Suppl. 1995;388:20-3. Review.

PMID:
7541599
11.

Conventional antipsychotic medications for schizophrenia.

Dixon LB, Lehman AF, Levine J.

Schizophr Bull. 1995;21(4):567-77. Review.

PMID:
8749885
12.

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.

Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.

PMID:
19411165
13.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
14.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, BurĂ³n JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group..

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
15.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
16.

Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB.

J Clin Psychiatry. 2003 Apr;64(4):451-8.

PMID:
12716249
17.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

18.

Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.

Lerner V, Libov I, Kotler M, Strous RD.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):89-98. Review.

PMID:
14687862
19.

Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.

Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S.

J Clin Psychiatry. 2001 Jul;62(7):545-51.

PMID:
11488366
20.

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.

Curr Med Res Opin. 2010 Mar;26(3):501-9. doi: 10.1185/03007990903488670.

PMID:
20014981

Supplemental Content

Support Center